Allergy Therapeutics plc has disclosed a Form 8.5 (EPT/RI) from Panmure Gordon (UK) Limited, an exempt principal trader with recognized intermediary status. The form provides key information regarding dealings in Allergy Therapeutics' securities. The dealings were undertaken on September 5, 2023. The form includes details of purchases and sales of the company's 0.1p ordinary shares, with the highest price per unit paid at 0.02666 and the lowest price per unit paid at 0.0262. The form does not disclose any cash-settled derivative transactions or stock-settled derivative transactions. It also states that there are no indemnity or option arrangements, agreements, or understandings relating to relevant securities. The contact person for this disclosure is Freddie Wooding, with a telephone number of +44 (0)20 7886 2969.